Placental Mesenchymal Dysplasia: Definition and Associated Risks
Placental mesenchymal dysplasia (PMD) is a rare, benign placental vascular and connective tissue disorder characterized by placentomegaly, cystic stem villi, and dilated chorionic vessels that carries substantial risks for both mother and fetus, including a 50% rate of fetal growth restriction, 18% risk of intrauterine fetal death, and 27% risk of maternal hypertensive complications.
What is Placental Mesenchymal Dysplasia?
PMD is a rare placental abnormality with unclear etiology that presents with distinctive pathological features 1, 2, 3:
Pathological Characteristics
- Placentomegaly (significantly enlarged placenta)
- Stem villous hyperplasia with thick-walled stromal vessels
- Cystic or grape-like edematous villi mixed with normal-appearing villi
- Abundant villous stroma with edema and mucoid degeneration
- Dilated and tortuous chorionic vessels often with thromboses
- Mild trophoblastic hyperplasia with pseudoinclusions
Immunohistochemical Profile
PMD shows p57 positivity in villous trophoblasts but negativity in villous stromal cells, which is crucial for distinguishing it from complete hydatidiform mole 1.
Imaging Findings
Ultrasound typically reveals 2, 3, 4:
- Cystic changes or hypoechoic areas within the placenta
- Placental enlargement
- Dilated chorionic vessels
- Honeycomb-like placental appearance
Critical diagnostic pitfall: PMD is frequently misdiagnosed as a partial hydatidiform mole on routine ultrasound, which can lead to unnecessary pregnancy termination 5, 6, 4. The key distinction is that PMD does not involve malignant trophoblastic disease and has a normal fetal karyotype (typically biparental diploid).
Associated Risks
Maternal Complications (27% overall) 6
- Hypertensive disorders: Preeclampsia and gestational hypertension occur in approximately 27% of cases
- Maternal serum markers: Elevated alpha-fetoprotein levels are common 3
- Mildly elevated β-hCG: Unlike molar pregnancy, β-hCG elevation is typically mild 4
Fetal/Perinatal Complications
High-risk outcomes 6:
- Fetal growth restriction: 50% of cases
- Intrauterine fetal death: 18% of cases
- Preterm delivery: 64% of live births
- Perinatal mortality: 35% of live-born infants died within the first 61 days
Neonatal complications in survivors 3, 6:
- Transient thrombocytopenia: 35% of live births
- Anemia: Reported in multiple cases
- Beckwith-Wiedemann Syndrome: Important association requiring tumor surveillance 7
- Hepatic tumors: Rare but documented
- Developmental delay: 7% in one series
Genetic Associations 6, 4
PMD has been associated with:
- Androgenetic/biparental chimerism in placental tissue
- Placental triploidy mosaicism
- CHARGE syndrome
- Fetal pleuropulmonary blastoma
- Fetal skeletal dysplasia
The fetal karyotype is typically normal biparental diploid, with a female predominance noted 4.
Clinical Management Implications
When PMD is suspected (cystic placental lesions on ultrasound) 5, 2:
- Prenatal invasive testing for fetal karyotype should be considered to exclude partial molar pregnancy 5
- Refer to regional fetal medicine center and GTD center for diagnostic uncertainty 5
- Enhanced maternal and fetal monitoring is essential given high complication rates 2, 4
- Serial ultrasound for fetal growth every 2-3 weeks
- Monitor for maternal hypertensive disorders
- Prepare for potential preterm delivery (occurs in 64% of cases)
Postnatally 7:
- Histopathological examination of placenta is mandatory
- Screen neonate for Beckwith-Wiedemann Syndrome if PMD confirmed
- Monitor for thrombocytopenia and anemia
- Consider tumor surveillance protocols if BWS features present
Reassuring note: Despite the high complication rates, a considerable proportion of maternal and fetal outcomes can be favorable with appropriate monitoring 2, 4. Unlike molar pregnancy, PMD does not require chemotherapy or prolonged β-hCG surveillance, and there is no increased risk of gestational trophoblastic neoplasia.
The critical distinction from partial hydatidiform mole cannot be overstated—misdiagnosis leads to inappropriate pregnancy termination in what may be a viable pregnancy with a normal fetus 6, 4.